GET DAILY SIGNALSKura Oncology (KURA): Weighing the Path Toward a $27 Analyst Target
Key Takeaways
- The central target used here is $27, the arithmetic mean of recent, verifiable analyst price targets reviewed for this article.
- Recent targets are unusually dispersed, ranging from roughly $12 to $40, reflecting deep disagreement over the launch trajectory of KOMZIFTI.
- With KURA recently trading near $7.57, reaching $27 would require a gain of roughly 257% — a very large move.
- Bullish analysts cite a strong early KOMZIFTI launch, a well-funded balance sheet, and the Kyowa Kirin collaboration as key supports.
- Bearish analysts point to a slowdown in launch momentum, persistent losses, and a sharp recent sell-off with two downgrades.
- Readers can explore Major News, Today's Price Move, Forecast, and Earnings for additional context on Kura Oncology.
- For a broader, AI-driven view of market opportunities, explore Trending AI Robots.
Analyst Price Targets and the Consensus Picture
The average analyst price target for KURA is best understood as a wide range rather than a tight consensus. Recent individual targets include J.P. Morgan at $30 (reiterated November 2026), Wedbush at $36 (November 2026), Bank of America Securities at $31 with a Buy rating (October 2026), Barclays at $28 with a Buy rating, H.C. Wainwright at $40 with a Buy rating, UBS at $16 with a Buy rating, Citizens at $24 with a Market Outperform rating, and Scotiabank at $10 with a Hold rating. Averaging the most current, attributable targets reviewed yields approximately $27. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Some aggregators report higher figures — from roughly $27 to $32 — because they retain older, elevated targets in their calculations. The Street's rating skews strongly bullish (a "Strong Buy" consensus), but the $12-to-$40 spread shows analysts disagree sharply on how quickly KOMZIFTI sales can scale and how much value the pipeline beyond AML deserves. The mean is a statistical midpoint, not a guarantee or an official published consensus.
Current Market Position and the Path Toward the Target
KURA shares recently closed around $7.57, near the low end of a 52-week range of $6.75 to $13.90. The stock has fallen more than 30% over the past month amid cautious sentiment ahead of third-quarter results and concerns about launch momentum. Reaching $27 from here implies roughly a 257% advance — a very large move for any established company, though not unprecedented for a small-cap biotech if pivotal data or commercial execution improve materially.
The path toward such a target would likely depend on accelerating KOMZIFTI revenue, positive combination data, and successful advancement of the frontline (KOMET-017) Phase 3 program. None of these outcomes is assured, and the stock's recent decline indicates investors are demanding evidence rather than projections.
What Could Support a Move Toward the Target
KOMZIFTI's early launch showed promise, with roughly $9.1 million in net product revenue over its first two quarters and a sequential increase of more than 50%, including majority share in the newly diagnosed NPM1-mutant AML setting. Kura's balance sheet is a key strength, with approximately $519 million in cash and short-term investments at mid-2026, plus expected Kyowa Kirin collaboration payments exceeding $180 million — management says this funds the core Phase 3 trial into 2028. Upcoming first ziftomenib–FLT3 inhibitor combination data at ASH 2026 could broaden the drug's addressable market, and expansion into frontline AML represents a substantially larger opportunity than the relapsed/refractory indication alone.
What Could Prevent the Target From Being Reached
The largest obstacle is execution risk in a competitive menin-inhibitor market that analysts increasingly expect to be shared rather than "winner-take-all." Consensus 2026 revenue forecasts were cut roughly 13% in recent months, and two analysts downgraded the stock. The company remains deeply unprofitable, with a GAAP net loss of about $279 million in 2025 and elevated operating expenses as it builds a commercial team and funds multiple trials. If launch uptake stalls, combination data disappoint, or the frontline trial slips, valuation compression could persist, and the wide analyst target range could narrow downward. Insiders selling shares in recent quarters has added to sentiment headwinds.
Technical Levels and Market Structure
The stock's recent breakdown from the $10 area toward the mid-$7s leaves it testing its 52-week low of $6.75, a critical support level. A durable prior trading zone near $9–$10 now acts as overhead resistance, and the $13.90 52-week high is the next major ceiling above that. The $12–$15 region, where several cautious analyst targets cluster, represents an intermediate psychological and technical hurdle. Until KURA reclaims and holds above the low-$10s, the technical structure remains weighted to the downside.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms differ. Key items to watch include quarterly KOMZIFTI net product sales and new-patient starts, the ASH 2026 ziftomenib combination data, any analyst target revisions or rating changes, cash runway updates, and milestone progress on the KOMET-017 frontline Phase 3 trial. Regulatory and competitive developments in the AML menin-inhibitor space also matter. None of these provides a definitive forecast.
Using AI Tools to Track Volatile Names
In my own process, I find it helpful to cross-check fundamental developments with systematic signals. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile name like KURA, such tools can help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual chart review. Traders seeking a systematic edge may find these signals a useful complement to fundamental research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KURA in upward trend: price may jump up because it broke its lower Bollinger Band on November 04, 2026
KURA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 39 of 43 cases where KURA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where KURA's RSI Indicator exited the oversold zone, 29 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where KURA advanced for three days, in 211 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KURA as a result. In 70 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for KURA turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 38 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for KURA entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. KURA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.354) is normal, around the industry mean (3.498). P/E Ratio (-2.157) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (12.821) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical services
Industry Biotechnology
Advertisement